Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals has reported Total Non-Current Liabilities for 9 years, with the latest figure at $75.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 13.99% year-over-year to $75.8 million; the trailing twelve-month figure through Mar 2026 stood at $75.8 million (down 13.99% YoY), and the FY2025 full-year result was $104.0 million, down 14.29% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $75.8 million, down from $104.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $164.0 million in Q3 2024, with the low at $75.8 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $115.0 million across 5 years, with a median of $116.4 million in 2023.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 37.49% — and 2025, when it plunged 38.23%.
• Agios Pharmaceuticals' Total Non-Current Liabilities stood at $134.6 million in 2022, then dropped by 7.19% to $124.9 million in 2023, then declined by 2.87% to $121.4 million in 2024, then decreased by 14.29% to $104.0 million in 2025, then decreased by 27.14% to $75.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $75.8 million (Q1 2026), $104.0 million (Q4 2025), and $101.3 million (Q3 2025), per Business Quant data.